Skip to main content
    I

    Inovio Pharmaceuticals Inc (INO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.04
    +0.05 (+5.48%)

    Market Cap: $101.95M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    46%(18/39)
    Avg Surprise
    -14.63%
    Streak
    3 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.20
    Range$-0.20 - $-0.19
    2 analysts
    EPS Revisions
    2
    0
    7d
    2
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.24+19.6%
    60d ago$-0.25+21.0%
    30d ago$-0.25+21.0%
    7d ago$-0.23+17.0%
    Current$-0.20
    Revenue Consensus
    $0
    Range$0 - $0
    3 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.04
    Range$0.04 - $0.04
    1 analysts
    Revenue Consensus
    $416670
    Range$-250000 - $2M
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.04---
    Sep 26EST
    		-$-0.20---
    Jun 26
    Reported Aug 12
    		$-0.07N/A+72.00%Beat+88.5%
    Mar 26
    Reported May 13
    		$-0.31$-0.33+6.06%Beat+39.2%
    Dec 25
    Reported Mar 12
    		$-0.28$-0.34+19.59%Beat+53.8%
    Sep 25
    Reported Nov 10
    		$-0.87$-0.48-81.25%Miss+2.2%
    Jun 25
    Reported Aug 12
    		$-0.61$-0.62+1.61%Beat+48.7%
    Mar 25
    Reported May 13
    		$-0.51$-0.74+31.08%Beat+61.1%
    Dec 24
    Reported Mar 18
    		$-0.60$-0.83+27.88%Beat+46.4%
    Sep 24
    Reported Nov 14
    		$-0.89$-1.13+21.24%Beat+42.9%
    Jun 24
    Reported Aug 8
    		$-1.19$-1.10-8.18%Miss+23.7%
    Mar 24
    Reported May 13
    		$-1.31$-0.99-32.32%Miss+31.8%
    Dec 23
    Reported Mar 6
    		$-1.12$-1.27+11.81%Beat-433.3%
    Sep 23
    Reported Nov 9
    		$-1.56$-1.50-4.00%Miss+13.3%
    Jun 23
    Reported Aug 9
    		$-1.56$-1.72+9.30%Beat+71.7%
    Mar 23
    Reported May 10
    		$-1.92$-1.80-6.67%Miss+55.6%
    Dec 22
    Reported Mar 1
    		$-0.21$-0.17-23.53%Miss+58.0%
    Sep 22
    Reported Nov 8
    		$-1.80$-3.27+44.95%Beat+48.3%
    Jun 22
    Reported Aug 9
    		$-5.52$-3.52-56.82%Miss-17.9%
    Mar 22
    Reported May 10
    		$-4.32$-3.93-9.92%Miss-33.3%
    Dec 21
    Reported Mar 1
    		$-0.50$-0.32-56.25%Miss-257.1%
    Sep 21
    Reported Nov 9
    		$-3.48$-3.62+3.87%Beat-26.1%
    Jun 21
    Reported Aug 9
    		$-4.68$-3.06-52.94%Miss+53.0%
    Mar 21
    Reported May 10
    		$-3.24$-2.34-38.46%Miss-3.8%
    Dec 20
    Reported Mar 1
    		$-0.14$-0.22+36.36%Beat+63.2%
    Sep 20
    Reported Nov 9
    		$-2.76$-2.30-20.00%Miss+0.0%
    Jun 20
    Reported Aug 10
    		$-9.96$-2.02-393.07%Miss-176.7%
    Mar 20
    Reported May 11
    		$-3.12$-2.85-9.47%Miss+13.3%
    Dec 19
    Reported Mar 12
    		$-0.38$-0.24-58.33%Miss-8.6%
    Sep 19
    Reported Nov 12
    		$-2.76$-3.07+10.10%Beat+14.8%
    Jun 19
    Reported Aug 8
    		$-3.60$-3.46-4.05%Miss-328.6%
    Mar 19
    Reported May 9
    		$-3.60$-3.06-17.65%Miss+16.7%
    Dec 18
    Reported Mar 12
    		$-0.35$-0.28-25.00%Miss-52.2%
    Sep 18
    Reported Nov 8
    		$-3.24$-3.54+8.47%Beat+30.8%
    Jun 18
    Reported Aug 7
    		$-0.84N/A+64.10%Beat+46.2%
    Mar 18
    Reported May 9
    		$-4.32$-3.24-33.33%Miss-16.1%
    Dec 17
    Reported Mar 14
    		$-0.23$-0.30+23.33%Beat+34.3%
    Sep 17
    Reported Nov 8
    		$-4.68$-3.05-53.44%Miss-
    Jun 17
    Reported Aug 8
    		$-1.56$-2.52+38.10%Beat-
    Mar 17
    Reported May 10
    		$-3.72$-3.75+0.80%Beat-
    Dec 16
    Reported Mar 15
    		$-0.35$-0.30-16.67%Miss-

    Key Metrics

    Valuation
    P/E Ratio-0.68EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-409.90%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio1.00xQuick Ratio1.00x
    Trading Statistics
    Beta1.61Avg Volume2.94M
    52-Week High$2.7252-Week Low$0.56

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.10
    SMA 20$1.15
    SMA 50$1.16
    SMA 200$1.31
    EMA 10$1.09
    EMA 20$1.13
    EMA 50$1.15
    EMA 200$1.33

    MACD

    Line: -0.04Signal: -0.02Hist: -0.02

    ADX

    ADX: 16.8+DI: 17.1-DI: 26.2

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down92.0
    PSAR$1.22

    Bollinger Bands

    Upper Band$1.32
    Lower Band$0.99
    %B Position2852%(Upper)
    Band Width0.15

    RSI (14-Day)

    Neutral
    41.3

    Momentum Oscillators

    Stoch %K18.7
    Stoch %D17.6
    Williams %R-71.0
    ROC (10d)-14.0%
    Momentum-0.17
    CCI (20d)-148.0
    MFI (14d)35.4

    Volatility Measures

    ATR (14d)$0.09(8.5%)
    StdDev (20d)0.08
    Hist Vol72.3%(High)

    Volume Flow

    VWAP$1.02
    OBV20.3M
    AD Line-75.0M
    CMF (20d)-0.261

    Volume Metrics

    Avg Vol (20d)2.9M
    Vol Ratio0.6x
    VWMA (20d)$1.14

    Pivot Points

    R3$1.08
    R2$1.05
    R1$1.02
    Pivot Point$0.99
    S1$0.96
    S2$0.93
    S3$0.89

    Advanced Oscillators

    TSI-14.22
    Ultimate Osc43.7
    KST-99.20

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$-65,343$0$0$65,343$116,994$0$100,762$0$102,650$388,446
    Cost of Revenue$0$0$754,054$0$0$0$775,829$0$0$0$175,227$0
    Gross Profit$0$0$-754,054$0$0$65,343$116,994$0$100,762$0$102,650$388,446
    Operating Expenses$18.62M$21.95M$17.48M$21.21M$23.08M$25.12M$20.49M$27.35M$33.30M$31.48M$27.50M$35.94M
    R&D$10.83M$14.07M$10.26M$13.33M$14.52M$16.09M$12.88M$18.73M$23.09M$20.91M$17.25M$15.50M
    SG&A$7.80M$7.88M$7.22M$7.88M$8.56M$9.02M$7.60M$8.61M$10.21M$10.57M$10.24M$9.93M
    Operating Income$-18,624,522$-21,949,993$-17,476,601$-21,210,455$-23,084,519$-25,050,529$-20,369,561$-27,347,479$-33,196,913$-31,484,969$-27,393,741$-35,553,012
    Interest Income$458,068$-1,585,018$67,294$167,749$2.15M$1.64M$88,519$2.76M$952,244$1.88M$4.46M$1.93M
    Interest Expense$0$0$0$0$0$0$0$0$0$177,833$282,325$313,488
    Income Before Tax$-4,297,838$-19,397,308$3.76M$-43,558,436$-22,816,229$-19,694,215$-17,472,434$-24,585,659$-32,244,669$-29,787,653$-22,714,864$-33,932,718
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-6,012,458$-19,682,798$3.76M$-45,496,672$-23,519,412$-19,694,697$-19,381,679$-25,165,478$-32,237,098$-30,469,871$-25,003,638$-33,929,864
    EBITDA$-3,998,052$-17,076,888$4.40M$-42,912,659$-24,233,476$-20,594,593$-16,965,375$-26,937,075$-32,838,459$-31,409,890$-28,262,893$-35,759,550
    EBIT$-4,755,906$-17,812,290$3.70M$-43,726,185$-24,962,529$-21,337,657$-17,560,953$-27,347,479$-33,196,913$-31,484,969$-27,393,741$-35,553,012
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about INO

    News

    Inovio Pharmaceuticals, Inc. (INO) Options Chain

    This article provides details on the options chain for Inovio Pharmaceuticals, Inc. (INO), including real-time stock prices, call and put options data, last trade dates, strike prices...

    Yahoo! Finance Canada•10/16/26•Neutral

    Inovio Pharmaceuticals stock has November 9 earnings date

    Inovio Pharmaceuticals (INO) is expected to report earnings on November 9, 2026. The company had cash and cash equivalents of USD 31.53 million as of June 30, 2026...

    ad-hoc-news.de•10/15/26•Somewhat-Bullish

    Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors

    Inovio Pharmaceuticals Inc. (INO) stock fell by 9.67% on Tuesday, closing at $1.00. This underperformance occurred during a generally poor trading session for the stock market...

    MarketWatch•10/14/26•Bearish

    Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors

    Shares of Inovio Pharmaceuticals Inc. (INO) fell 3.91% on Monday, closing at $1.11, despite a mixed trading session for the broader market. The stock underperformed competitors...

    MarketWatch•10/12/26•Bearish

    Price to sales ratio of Inovio Pharmaceuticals, Inc. – HAN:GBM

    This article displays the price to sales ratio for Inovio Pharmaceuticals, Inc. (GBM) on the Hannover Stock Exchange. The data is presented as a value and percentage change over a period...

    TradingView•10/12/26•Neutral

    INO Valuation and Fair Value

    P/E
    -0.7x
    Forward P/E
    16.6x
    PEG
    0.0x
    P/B
    19.4x
    See GNG's fair value

    INO Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -409.9%

    INO Competitors

    CompanyTicker
    Unicycive Therapeutics IncUNCY
    Corbus Pharmaceuticals HoldingCRBP
    PDS Biotechnology CorpPDSB
    Humacyte IncHUMA
    Armata Pharmaceuticals IncARMP
    The Joint CorpJYNT
    Vivani Medical Inc.VANI
    PolyPidPYPD

    Sector: Healthcare

    INO Analyst Ratings

    Consensus
    Buy
    Analysts
    3
    Strong Buy
    1
    Buy
    0
    Hold
    2
    Sell
    0
    Strong Sell
    0

    INO Bull Case vs Bear Case

    Bull case

    • INO beat EPS estimates in 87.5% of its last 8 reported quarters.

    Bear case

    • INO's quarterly revenue changed -100.0% year over year.

    INO Earnings: Beat Rate and Next Report

    Beat rate
    7 of 8 quarters (87.5%)
    Average surprise
    12.3%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.20
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    2 up, 0 down

    Frequently Asked Questions About INO

    Does INO pay dividends?

    Inovio Pharmaceuticals Inc (INO) does not currently pay a regular dividend.

    What is INO's market cap?

    Inovio Pharmaceuticals Inc (INO) has a market capitalization of $101.95M with a current stock price of $1.04.

    Related stocks

    Sector: Healthcare

    All stocks starting with I

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In